

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – January 26, 2005

NOTICE OF STATUS CHANGE

Study 2 is temporarily closed to patient accrual effective immediately **Wednesday, January 26, 2005**. Accrual to dose level 1E has been met.

Please retain this notice with the protocol.